United States · FDA National Drug Code directory
FLUZONE TRIVALENT NORTHERN HEMISPHERE
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 49281-426_775d34bb-508b-47ef-af40-d4dbf8ea132c
- Product NDC
- 49281-426
- Form
- INJECTION, SUSPENSION
- Composition / generic term
- INFLUENZA A VIRUS A/Switzerland/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED), INFLUENZA A VIRUS A/Michigan/105/2025 SAN-049A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED), and INFLUENZA B VIRUS B/Tokyo/EIS13-175/2025 ANTIGEN (FORMALDEHYDE INACTIVATED)
- Labeler
- Sanofi Vaccines US Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240702 / 20270630
Source-listed ingredients
- INFLUENZA A VIRUS A/SWITZERLAND/6849/2025 IVR-278 (H1N1) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mg
- INFLUENZA A VIRUS A/MICHIGAN/105/2025 SAN-049A (H3N2) ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mg
- INFLUENZA B VIRUS B/TOKYO/EIS13-175/2025 ANTIGEN (FORMALDEHYDE INACTIVATED) — 15 ug/.5mg
These values do not establish equivalence or a dose recommendation.
Packages
- 10 SYRINGE, GLASS in 1 PACKAGE (49281-426-50) / .5 mg in 1 SYRINGE, GLASS (49281-426-88) · 49281-426-50
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →